Treatment of hyperactivity in children with pervasive developmental disorders

Journal of Child and Adolescent Psychiatric Nursing

Volumn 20, Issue 1, 2007, Pages 59-62

  Scahill, Lawrence ^a   Pachler, Maryellen ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMANTADINE; CENTRAL STIMULANT AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GUANFACINE; METHYLPHENIDATE; NALTREXONE; NARCOTIC ANTAGONIST;

ATTENTION DEFICIT DISORDER; AUTISM; CHILD; CHILD PSYCHIATRY; HUMAN; METHODOLOGY; PATIENT SELECTION; REVIEW; TREATMENT OUTCOME;

ADRENERGIC ALPHA-AGONISTS; AMANTADINE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD PSYCHIATRY; DOPAMINE AGENTS; GUANFACINE; HUMANS; METHYLPHENIDATE; NALTREXONE; NARCOTIC ANTAGONISTS; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 34147141338     PISSN: 10736077     EISSN: 17446171     Source Type: Journal    
DOI: 10.1111/j.1744-6171.2007.00080.x     Document Type: Article

References (13)

1. Aman, M.G. (2004) Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Seminars in Pediatric Neurology, 11 (3), 225-228.
2. Aman, M.G., Lam, K.S., & Van Bourgondien, M.E. (2005). Medication patterns in patients with autism: Temporal, regional, and demographic influences. Journal Child Adolescent Psychopharmacology, 15 (1), 116-126.
3. Campbell M., Anderson, L.T., Small, A.M., Adams, P., Gonzalez, N.M., & Ernst, M. (1993). Naltrexone in autistic children: Behavioral symptoms and attentional learning. Journal American Academy Child Adolescent Psychiatry, 32, 1283-1291.
4. Campbell M., Overall, J.E., Small, A.M., Sokol, M.S., Spencer, E.S., Adams, P., et al. (1989). Naltrexone in autistic children: An acute open dose range tolerance trial. Journal American Academy Child Adolescent Psychiatry, 28, 200-206.
5. King, B.H., Wright, D.M., Handen, B.L., Sikich, L., Zimmerman, A.W., McMahon, W., et al. (2001). Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal American Academy Child Adolescent Psychiatry, 40, 658-665.
6. Kolmen, B.K., Feldman, H.M., Handen, B.L., & Janosky, J.E. (1997). Naltrexone in young autistic children: Replication study and learning measures. Journal American Academy Child Adolescent Psychiatry, 36, 1570-1578.
7. Multimodal Treatment of ADHD Group (MTA) Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives General Psychiatry, 56, 1073-1086.
8. Multimodal Treatment of ADHD Group (MTA) Cooperative Group. (2004). Changes in effectiveness and growth after the end of treatment. Pediatrics, 113 (4), 762-769.
9. Research Units on Pediatric Psychopharmacology Autism Network. (2005). A randomized controlled crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives General Psychiatry, 62, 1266-1274.
10. Rains, A., & Scahill, L. (2006). Nonstimulant medications for the treatment of ADHD. Journal Child Adolescent Psychiatric Nursing, 19 (1), 44-47.
11. Rains, A., & Scahill, L. (2004). New long-acting stimulants in children with ADHD. Journal Child Adolescent Psychiatric Nursing, 17 (4), 177-179.
12. Scahill, L. Carroll, D., & Burke, K. (2004). Methylphenidate: Mechanism of action and clinical update. Journal Child Adolescent Psychiatric Nursing, 17 (2), 85-86.
13. Scahill, L., Aman, M.G., McDougle, C.J., McCracken, J.T., Tierney, E., Dziura, J., et al. (2006). An open prospective trial of guanfacine in children with pervasive developmental disorders. Journal Child Adolescent Psychopharmacology, 16 (5), 589-598.